Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278915 | PMC |
| http://dx.doi.org/10.1136/bmjgh-2018-001143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.
Acta Neuropathol Commun
January 2025
Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Glioblastoma (GBM) is a highly aggressive adult brain cancer, characterised by poor prognosis and a dismal five-year survival rate. Despite significant knowledge gains in tumour biology, meaningful advances in patient survival remain elusive. The field of neuro-oncology faces many disease obstacles, one being the paucity of faithful models to advance preclinical research and guide personalised medicine approaches.
View Article and Find Full Text PDFA Jump Into Cold Water or a Leap of Faith?
J Neuropsychiatry Clin Neurosci
January 2025
Extreme Environments Laboratory, University of Portsmouth, Portsmouth, United Kingdom.
On the origin of life on earth.
AIDS Rev
June 2024
Philosophy School, University of Navarra, Pamplona, Spain.
The creation of the universe out of nothing (ex nihilo) is attributable to the eternal God. Would a direct divine intervention be needed for other singular events, such as the origin of life? Taking apart the human being, created to image and resemblance of God, we argue that current scientific knowledge allows us to rationally admit a continuity between the origins of the universe and the emergence of life on Earth. Although the irruption of living beings from inert matter is a leap or discontinuity in creation, a direct intervention of God would not be indispensable.
View Article and Find Full Text PDFPET/CT in aortic grafts: Sufficient evidence or still leap of faith?
J Nucl Cardiol
June 2024
Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Nuclear Cardiology Unit, Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Electronic address:
FIGO 2023 endometrial staging: a leap of faith into the new "prognostic based' rather than "anatomical based" staging-too fast too furious??
J Cancer Res Clin Oncol
May 2024
Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India.
Background: In 2023 FIGO revised the endometrial cancer staging system after 13 years. There is a lacuna of data regarding the performance and practicality of the revised 2023 FIGO staging schema for endometrial cancer from Low Middle-Income Countries (LMIC).
Objective: To estimate the shift of stage and adjuvant management of endometrial cancer based on the FIGO 2023 system compared to the FIGO 2009 system and assess the predictive potential of the FIGO 2023 system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!